19-362 - Safety and Pharmacokinetics Study of MK-5890 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)
Status: openA Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors
Treatment for Advanced Solid Tumors
Description
The purpose of this study is to assess the safety and pharmacokinetics of MK-5890 when administered alone and in combination with pembrolizumab (MK-3475) in adults with advanced solid tumors. The initial course of MK-5890 monotherapy or MK-5890 plus pembrolizumab combination therapy will be for up to 35 administrations (approximately 2 years). The safety and pharmacokinetics of MK-5890 when administered with pembrolizumab, pemetrexed and carboplatin will also be assessed in adults with non-squamous non-small cell lung cancer (NSCLC).
Sponsors
This trial is sponsored by University of Chicago.Interested in Clinical Trial?
Contact the Clinical Trial Coordinator
If you have questions get in touch with this Clinical Trial’s Coordinator by phone at (251) 445-9834 or by email at wlblount@health.southalabama.edu.
Providers Associated With This Trial
Principle Investigator
View Profile
Sachin Pai, M.D., M.S.C.I.Medical OncologistProgram Leader of Developmental Therapeutics; Assistant Professor of Interdisciplinary Clinical Oncology
Sub Investigators
View Profile
Teja Poosarla, M.D.Medical Oncologist and HematologistAssistant Professor of Interdisciplinary Clinical OncologyView Profile
Jennifer M. Scalici, M.D.Gynecologic OncologistChief of Gynecologic Oncology Service; Professor of Interdisciplinary Clinical OncologyView Profile
Rodney P. Rocconi, M.D., F.A.C.O.G.Gynecologic OncologistAssociate Director for Clinical Research; Abraham A. Mitchell Clinical Cancer Research Scholar; Professor of Interdisciplinary Clinical OncologyView Profile
Nathaniel Jones, M.D.Gynecologic OncologistAssistant Professor of Interdisciplinary Clinical OncologyView Profile
Jennifer Young Pierce, M.D., M.P.H., F.A.C.O.G.Gynecologic OncologistResidency Program Director for Obstetrics and Gynecology; Leader of Cancer Control and Prevention; Professor of Interdisciplinary Clinical Oncology